Market_Access

Tonix adds 21 million Medicare lives for TONMYA in second payer deal

Image
Tonix adds 21 million Medicare lives for TONMYA in second payer deal

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced on September 22, 2026 a second managed Medicare agreement for its fibromyalgia drug TONMYA, adding about 21 million Medicare lives. Medicare coverage for TONMYA now totals 32 million lives, or 58% of about 55 million Medicare lives in the U.S.

The agreement took effect immediately. By our calculation, it nearly triples earlier Medicare coverage: 32 million minus 21 million leaves about 11 million lives before the deal, roughly 20% of the Medicare population, against 58% now.

Total payer coverage for TONMYA reaches 53% of U.S. lives

Tonix says commercial and government coverage now totals about 166 million lives, 53% of about 314 million U.S. lives. Medicare accounts for about 19% of that total (32 million of 166 million). By our calculation, about 148 million lives, or 47%, remain outside coverage.

CARsgen's satri-cel joins China's commercial insurance drug list

Image
CARsgen's satri-cel joins China's commercial insurance drug list

SHANGHAI -- November 19, 2026 -- China's National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) have added CARsgen's CAR T-cell therapy satri-cel to the 2026 Commercial Health Insurance Innovative Drug List (CHIIDL). The listing comes about five months after the National Medical Products Administration approved the product in June 2026.

Satri-cel (satricabtagene autoleucel, code CT041) targets Claudin18.2. The listed indication is Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. CARsgen trades in Hong Kong under stock code 2171.HK.